• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott’s FreeStyle Libre wins reimbursement in Japan

August 31, 2017 By Sarah Faulkner

AbbottAbbott (NYSE:ABT) said today that the Ministry of Health Labor and Welfare in Japan has granted national reimbursement for the company’s FreeStyle Libre glucose monitoring system.

The FreeStyle Libre system uses a small sensor worn on the back of the upper arm to measure glucose every minute in interstitial fluid through a filament inserted under the skin. Abbott said its system can produce a glucose reading painlessly in less than 1 second by scanning a reader over the sensor.

“This is a significant development for the Japanese diabetes community – both for the people living with the condition and for their healthcare professionals,” Jared Watkin, SVP of Abbott’s Diabetes Care division, said in prepared remarks. “FreeStyle Libre has had a demonstrable impact around the world in helping people with diabetes, and we are pleased with the MHLW decision to make the product available through government reimbursement to those who need it.”

In February,  Abbott touted results from real-world use data for its FreeStyle Libre system. The data showed that people using its technology to monitor their glucose levels spend less time in hypoglycemia or hyperglycemia and have improved average glucose levels.

“For people living with diabetes frequent glucose measurement is key to effective diabetes management. It is often challenging for my patients to comply with glucose testing because of the pain, inconvenience and stigma of using finger sticks,” Dr. Yoshihito Atsumi, director of the Diabetes Center at Eiju General Hospital, added. “FreeStyle Libre not only enables my patients to check their glucose more frequently due to the convenience of the technology, but it also provides valuable glucose trends and patterns to help me make more informed treatment decisions.”

Japan’s decision puts the country in a group with 16 others that have partially or fully covered FreeStyle Libre, including France and Germany. The system is being reviewed by the FDA in the U.S.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Diabetes, Featured, Regulatory/Compliance, Wall Street Beat Tagged With: abbott

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS